C Difficile

A clinician provides insights on this significant topic as well as resources in finding information on them.

CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video. Allegretti presented data at Digestive Disease Week on safety outcomes and concomitant medication changes after treatment with Rebyota (fecal microbiota,

Fecal microbiota transplants are the most effective and affordable treatment for recurrent infections with Clostridioides difficile, an opportunistic bacterium and the most common cause of hospital-acquired intestinal infections. However, attempts to treat chronic noncommunicable diseases such as ulcerative colitis and metabolic syndrome via fecal microbiota transplantation (FMT) have yielded mixed results. Two review articles publishing May 10 in the journal Cell Host and Microbe discuss what we do and don’t know about why FMTs work (when they do).

Allowing nurses to order Clostridioides difficile testing without a physician's approval could help hospitals lower infection rates, a new study suggests.

Researchers sought to determine a method of testing hematopoietic stem cell transplantation recipients for Clostridium difficile as a cause of diarrhea.

Hospital policies allowing nurses to independently initiate testing for the bacterium C. difficile could reduce infection spread and associated morbidity.

Patients with C. difficile who received clonal bacteria populations via biotherapeutic injection were able to repopulate their microbiota with commensal bacteria.

Findings suggest policy change expedites availability of test results, and could help decrease clinical and economic burden of C. difficile infections.

A new study showed an introduction of beneficial microbiota.

What is the "optimal formula" for donor selection and feces processing for fecal microbiota transplantation in ulcerative colitis?

Fecal microbiota transplantation (FMT) is highly effective in preventing recurrent Clostridioides difficile infection (rCDI). However, the mechanisms underpinning its clinical efficacy are incompletely understood. Herein, we provide an overview of rCDI pathogenesis followed by a discussion of potent …

Fecal microbiota transplantation (FMT) has achieved satisfactory results in preventing the recurrence of Clostridioides difficile infection, but these positive outcomes have only been partially replicated in other diseases. Several factors influence FMT success, including those related to donors and …

The microbiome plays a vital role in maintaining homeostasis of the intestinal microenvironment and immune response in allogeneic hematopoietic cell transplantation (HCT) recipients. Disruption of the intestinal microbiome has been associated with the development of acute graft-versus-host disease ( …

As a long-term condition that affects the airways and lungs, chronic obstructive pulmonary disease (COPD) is characterized by inflammation, emphysema, breathlessness, chronic cough, and sputum production. Currently, the bronchodilators and anti-inflammatory drugs prescribed for COPD are mostly off-t …

Clostridioides difficile, which causes life-threatening diarrheal disease, is considered an urgent threat to healthcare setting worldwide. The current standards of care solely rely on conventional antibiotic treatment, however, there is a risk of promoting recurrent C. difficile infection (rCDI) bec …

Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com

Clostridioides difficile infection (CDI) represents a significant challenge to public health. C. difficile-associated mortality and morbidity have led the U.S. CDC to designate it as an urgent threat. Moreover, recurrence or relapses can occur in up to a third of CDI patients, due in part to antibio …

Hospital coding of CDI and notification to authorities has approximately halved from 2015 to 2021. Potential influential factors include hospital hygiene campaigns, implementation of antibiotic stewardship programs, social distancing due to the COVID-19 pandemic, and a decrease in more pathogenic su …

Clostridioides difficile colonizes up to 30-40% of community-dwelling adults without causing disease 1, 2 . C. difficile infections (CDIs) are the leading cause of antibiotic-associated diarrhea in the U.S. 3, 4 and typically develop in individuals following disru …

Several studies suggest that butyrate may be important in alleviating gut infections, such as reducing inflammation caused by the healthcare-associated Clostridioides difficile . While studies in both animal models and human studies correlate high levels of butyrate with reduced C. diffici …

Clostridioides difficile, which causes life-threatening diarrheal disease, is considered an urgent threat to healthcare setting worldwide. The current standards of care solely rely on conventional antibiotic treatment, however, there is a risk of promoting recurrent C. difficile infection (rCDI) bec …

A species of ordinary gut bacteria that we all carry flourishes when the intestinal flora is knocked out by a course of antibiotics.

Flagella are the main motility structure of Clostridioides difficile that affects the adhesion, colonization, and virulence of C. difficile in the human gastrointestinal tract. The FliL protein is a single transmembrane protein bound to the flagellar matrix. This study aimed to investi …

The comparative genomic analysis of Lactiplantibacillus plantarum YW11t (L. plantarum YW11) isolated from Tibetan kefir involves comparison of the complete genome sequences of the isolated strain with other closely related L. plantarum strains. This type of analysis can be used t …

Infectious colitis is inflammation of the intestines resulting from an underlying bacterial, viral, or parasitic infection. Learn more here.

New York, USA, May 03, 2023 (GLOBE NEWSWIRE) -- Clostridium difficile Infections Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight The

An infectious disease-led C. difficile testing approval process was feasible and associated with a 50% decrease in HO-CDI rates, due to enforcement of appropriate testing.

After a recent $106.5m fundraise, the designation marks another milestone for the company set to start a Phase III study later this year.

Excellent talk at #DDW2023 by Dr. ⁦@CTropini⁩ on creating a healthy gut microbiome environment. You wouldn’t “plant trees during a forest fire”. We need to create the gut environment (e.g pH, osmolality) to increase survival of #FMT treatment. ⁦@getgutsycanada⁩ pic.twitter.com/CNfspRloX4— Kate Lee (@KateLeeIBD) May 9, 2023

Ferring’s Rebyota therapeutic was studied in this population and demonstrated a 79% efficacy.